KYMR Q4 2023 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$48M+196.7% YoY

Gross Profit

$48M100.0% margin

Operating Income

-$19M-40.3% margin

Net Income

-$14M-30.0% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+912.8%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

-$4M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$576M

Total Liabilities

$181M

Stockholders' Equity

$395M

Cash & Equivalents

$110M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$48M	$16M	+196.7%
Gross Profit	$48M	$16M	+196.7%
Operating Income	-$19M	-$39M	+50.0%
Net Income	-$14M	-$35M	+58.8%